Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Seres Therapeutics (MCRB) PT Lowered to $17 at Oppenheimer
August 3, 2018 9:25 AM EDTOppenheimer lowered its price target on Seres Therapeutics (NASDAQ: MCRB) to $17.00 (from $18.00) while maintaining a Outperform rating.
... MoreSeres Therapeutics (MCRB) Misses Q2 EPS by 5c, Revenues Miss
August 2, 2018 7:20 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.68), $0.05 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.57 million.
Seres has made excellent progress across our deep pipeline of early and late, clinical and preclinical stage microbiome programs,... More
